What is the relationship between depression and heart health?
The relationship between depression and physical health is well established. Depression is consistently associated with poorer overall health outcomes, increased physiological burden, and elevated mortality risk.
Among these associations, the link between depression and cardiovascular health is particularly clear. Individuals with Major Depressive Disorder have approximately a twofold increased risk of developing cardiovascular disease, and depression is present in up to 20–30% of patients with established cardiac conditions.
This convergence reflects shared regulatory systems. The neural networks that govern mood, stress physiology, and autonomic control are deeply interconnected. The heart- continuously regulated by these systems- becomes a measurable expression of how effectively that regulation is functioning.
What does the heart tell us about nervous system state in depression?
Heart rate and heart rate variability (HRV) are direct indices of autonomic nervous system function. The autonomic system maintains balance between sympathetic activation and parasympathetic recovery, modulating internal stability in response to demand.
In depression, this balance is frequently altered. Elevated resting heart rate and reduced HRV are consistently observed, reflecting diminished parasympathetic tone and reduced regulatory flexibility.
These findings indicate altered control within central regulatory networks. The heart provides an accessible and quantifiable marker of this nervous system state.
How are the brain’s emotional circuits connected to cardiac regulation?
The brain regions central to depression- including the cortex and the limbic system- are also involved in autonomic regulation.
These areas interact with pathways that influence vagal activity to the heart. The vagus nerve plays a defining role in parasympathetic cardiac control, slowing heart rate and supporting physiological recovery.
This integrated system- often described as the frontal-vagal network- links executive regulation, emotional processing, and cardiac function within a shared architecture. When this network is disrupted, changes may emerge both in mood and in heart rate dynamics.
The relationship between brain and heart is therefore structural and functional, not coincidental.
What is the relationship between rTMS and heart rate in depression?
Repetitive Transcranial Magnetic Stimulation (rTMS) produces effects beyond cortical modulation alone. Stimulation of the dorsolateral pre-frontal cortex has been shown to slow down heart rate in healthy individuals, as well as those suffering from depression. Effective rTMS treatment is also associated with the normalisation of heart rate and HRV, further illustrating the bidirectional relationship.
What these shifts suggest is that rTMS engages the broader heart–brain regulatory network. Emerging evidence also suggests that greater decrease in heart rate early in treatment may be associated with a stronger clinical response.
Taken together, this suggests that heart rate changes reflect effective engagement of the relevant brain network during rTMS.
How can heart–brain coupling enable precision neuromodulation and personalised rTMS?
Psychiatry is increasingly moving toward stratified and personalised intervention. Connectivity between the cortex and the limbic system is one of the strongest predictors of rTMS response. However, this connectivity profile varies between individuals.
Several rTMS targets demonstrate therapeutic efficacy, and most clinics simply select one of those locations. Yet evidence supports multiple viable targets- and not all are equally effective for every patient.
At NAYA Health, we apply a heart–brain coupling approach to guide precision neuromodulation.
By measuring heart rate deceleration across four evidence-based stimulation sites, we identify the location that most effectively engages the individual’s regulatory brain network. Target selection is therefore informed by measurable autonomic response rather than protocol convention.
This enables genuinely personalised rTMS treatment, grounded in physiological data.
What does this mean for the future of personalised rTMS?
NAYA Health is currently the only clinic in the UK offering neurocardiac-guided rTMS.
This represents a shift from protocol-based delivery to biologically informed intervention. By integrating cardiac response into target selection, neuromodulation becomes adaptive rather than standardised.
As the field advances, precision will increasingly define clinical excellence. The ability to observe physiological response in real time allows treatment to move beyond anatomical assumption and toward demonstrable network engagement.
Heart–brain coupling reflects a more exacting model of care- one in which stimulation is selected not because it is conventional, but because it is biologically responsive.
This is the next evolution of personalised rTMS- grounded not only in symptoms, but in measurable network engagement.